AlzeCure Pharma CEO Martin Jonsson and CSO Johan Sandin. (AlzeCure Pharma) Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease ...

First, let's take a look at Lilly's path to GLP-1 dominance and consider why the stock has taken off recently. Novo Nordisk entered this market first, back in 2017, with Ozempic, which regulators ...

LimmaTech's lead program targets S. aureus, a major cause of surgical-site infections Vaccine Company acquisition includes experimental vaccine for Epstein-Barr virus Curevo is developing shingles ...

Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its buying spree into viral and bacterial pathogen R&D.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Eli Lilly said Tuesday it would buy ...

IMDb.com, Inc. übernimmt keine Verantwortung für den Inhalt oder die Richtigkeit der oben genannten Nachrichtenartikel, Tweets oder Blog-Beiträge. Dieser Inhalt wird nur zur Unterhaltung unserer ...

Since the start of the decade, Eli Lilly has committed to spend more than $50 billion to bolster its United States manufacturing capabilities. But even that’s not enough to meet the needs of the ...

In 1876, Colonel Eli Lilly opened a small pharmaceutical company in Indianapolis with an idea that was, at the time, radical to some: make medicine that actually worked. He had witnessed soldiers die ...

So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will spend $7 billion to acquire privately held Kelonia Therapeutics and its KLN-1010 CAR-T gene therapy drug ...

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Eli Lilly’s LLY-0.64%decrease; down pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 study ...